Pancreatic Cancer Research

ResearcherDalian Medical UniversityActive in the last 2 years

Jiwei Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5040-6242; OpenAlex author ID A5101826858. Sources: OpenAlex.

Their work

Papers
5 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
11
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 5

  1. USP10 activates the FAK pathway by stabilizing RIOK3 in pancreatic ductal adenocarcinoma Last author DOI 10.21203/rs.3.rs-3941004/v1↗
  2. RIOK3 promotes mTORC1 activation by facilitating SLC7A2-mediated arginine uptake in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/aging.204528↗
  3. Tissue metabolomics identified new biomarkers for the diagnosis and prognosis prediction of pancreatic cancer. Co-author DOI 10.3389/fonc.2022.991051↗
  4. USP22 promotes epithelial-mesenchymal transition via the FAK pathway in pancreatic cancer cells. Co-author DOI 10.3892/or.2014.3354↗
  5. Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis. Co-author PMID 24966957↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Henan Qin · 3 shared papers, 2022–2024 · strength 0.52
  2. Zhen Ning · 4 shared papers, 2014–2024 · strength 0.47
  3. Aman Wang · 4 shared papers, 2014–2023 · strength 0.43
  4. Peiyuan Yin · 2 shared papers, 2022–2024 · strength 0.34
  5. Shuang Li · 1 shared paper, 2024 · strength 0.19
  6. Rui Sun · 1 shared paper, 2024 · strength 0.19
  7. Mengyuan Xu · 1 shared paper, 2023 · strength 0.18
  8. Chang Liu · 1 shared paper, 2022 · strength 0.15
  9. Haihua Liu · 1 shared paper, 2022 · strength 0.15
  10. Dong Shang · 1 shared paper, 2022 · strength 0.15
  11. Zhongyu Wang · 2 shared papers, 2014 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.